Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Neurology Drugs in Phase I Clinical Development in SWITZERLAND

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              AC Immune

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

              Contact the Supplier

              Lead Product(s): ACI-3024

              Therapeutic Area: Neurology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $105.1 million Upfront Cash: Undisclosed

              Deal Type: Collaboration March 23, 2020

              Details:

              The collaboration combines AC Immune’s proprietary Morphomer discovery platform technology and early development experience with Lilly’s clinical development expertise and commercial capabilities.

              Idorsia Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy

              Contact the Supplier

              Lead Product(s): ACT-709478

              Therapeutic Area: Neurology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Neurocrine Biosciences

              Deal Size: $417.0 million Upfront Cash: $45.0 million

              Deal Type: Licensing Agreement January 10, 2020

              Details:

              Under this agreement, Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsy.

              PharmaCompass__DigitalAd